Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

INTRODUCTION: Ixekizumab (IXE) is an IgG4-type monoclonal antibody targeting IL-17A indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients with insufficient response or with intolerance to one or more disease-modifying anti-rheuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Joven, Beatriz, Hernández Sánchez, Raquel, Pérez-Pampín, Eva, Aragón Díez, Ángel, Almodóvar, Raquel, Martínez-Ferrer, Ángels, Belzunegui, Joaquín, Rubio, Esteban, Díaz-Cerezo, Silvia, Moyano, Sebastián, Gómez-Barrera, Manuel, Yébenes, María, Núñez, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468471/
https://www.ncbi.nlm.nih.gov/pubmed/37481752
http://dx.doi.org/10.1007/s40744-023-00584-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468471/
https://www.ncbi.nlm.nih.gov/pubmed/37481752
http://dx.doi.org/10.1007/s40744-023-00584-8

Ejemplares similares